Eli Lilly and Company
LLY
$733.51
$8.641.19%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 3,914.81% | -103.26% | 31.10% | -30.59% | 33.48% |
| Total Depreciation and Amortization | -5.67% | 12.20% | 1.10% | -3.39% | 3.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -72.87% | 258.59% | -367.24% | -180.77% | 133.15% |
| Change in Net Operating Assets | -499.87% | 194.42% | -612.00% | 119.91% | -188.85% |
| Cash from Operations | -114.25% | 246.49% | -63.49% | 4.08% | -24.99% |
| Capital Expenditure | -10.34% | -31.44% | -10.43% | -33.51% | 18.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 61.64% | -856.07% | 1,474.88% | 82.44% | 65.81% |
| Cash from Investing | 5.07% | -570.99% | 33.35% | 27.00% | 1.24% |
| Total Debt Issued | 4,636.49% | -- | -100.00% | 1,727.00% | 35.28% |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.19% | 0.16% | -0.06% | -15.02% | -0.25% |
| Other Financing Activities | -364.71% | 56.41% | 94.45% | -1,951.09% | -163.46% |
| Cash from Financing | 519.70% | 155.35% | -350.64% | 136.12% | 9.65% |
| Foreign Exchange rate Adjustments | 2,339.62% | -42.39% | -62.90% | 119.34% | -3,461.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 239.56% | 63.15% | -157.57% | 368.70% | -9,907.27% |
